GSK

Business Context and Reporting Period

This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2016. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), or Connected Persons, specifically regarding the vesting of conditional share awards under the GlaxoSmithKline Performance Share Plan.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation events. The only financial data points provided are the closing share prices at the time of vesting on February 12, 2016:

• Ordinary Share: £13.635
• American Depositary Share (ADS): US$39.76

Material Changes

The filing details the vesting and lapsing of performance share awards granted in 2013 and 2014. The performance periods concluded on December 31, 2015. Specific vesting outcomes for the named individuals are as follows:

Dividends accrued on vested awards were included in the same proportion as the underlying shares.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management outlook, risks, contingencies, or unusual items. The document is a regulatory disclosure of past compensation events and does not contain forward-looking financial statements.

Investor Verification Checklist

• Verify the total number of shares vested versus lapsed for the specific performance periods (2013-2015 and 2014-2015) to assess executive retention and performance alignment.
• Confirm the valuation of the vested awards using the reported closing prices (£13.635 for Ordinary Shares and US$39.76 for ADS) on February 12, 2016.
• Review the specific business performance conditions attached to the 2013 and 2014 awards to understand the criteria met for vesting.